InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,708.75
(
-0.93%
)
US TECH 100
19,247.55
(
-1.41%
)
Dow Jones
42,156.97
(
-0.41%
)
Brent Oil
74.30
(
3.21%
)
Bitcoin
60,640.42
(
-4.26%
)
Post# of 253265
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120523
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: crudeoil24 post# 228784

Wednesday, 02/26/2020 5:42:48 PM

Wednesday, February 26, 2020 5:42:48 PM

Post# of 253265
ESPR—FDA approves Nexletol/Zetia FDC called Nexlizet:

https://www.globenewswire.com/news-release/2020/02/26/1991460/0/en/Esperion-Announces-FDA-Approval-of-the-NEXLIZET-bempedoic-acid-and-ezetimibe-Tablet-an-Oral-Once-Daily-Non-Statin-LDL-Cholesterol-Lowering-Medicine.html

By incorporating a dual LDL-lowering MoA, Nexlizet can reduce LDL for some patients beyond what can be accomplished with Nexletol monotherapy.

Each Nexlizet tablet contains 180mg of Nexletol and 10mg (generic) Zetia. (Zetia has been off-patent in the US for several years.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up